This will be important in determining the clinical translatability of targeting these proteins in advanced prostate cancer, although, as discussed, changes in BCL-2 proteins are dynamic, and this cannot be evaluated with immunohistochemical studies. The gene discussed is BCL2; the disease is prostate carcinoma.